Plain-English translation of NCT03755193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing what happens when people with osteoporosis switch to different bone-strengthening medications after receiving denosumab for two years. Researchers want to compare three different treatment approaches to see which one is most effective and safest for Japanese patients with weak bones.
Many people with osteoporosis take denosumab, but doctors need to know the best way to continue treatment afterward. This study will help show whether switching to other medications works well and whether combining treatments is more beneficial than taking one medication alone.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of three groups: take one medication alone, or take one medication combined with a second medication, for 24 months. Throughout the study, you would have regular visits to take your medications as prescribed, and doctors would monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Japan
Phase
Testing effectiveness
Sponsor
Shinshu University
Enrollment target
~90 participants
Started
November 2018
Primary completion
November 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years – 120 Years
Last updated on clinicaltrials.gov in September 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yukio Nakamura
Shinshu University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.